PCM
IMNM icon

Prelude Capital Management’s Immunome IMNM Stock Holding History

Prelude Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-80,742
Closed -$543K – 1162
2025
Q1 		$543K Buy
+80,742
New +$775K 0.04% 482

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Prelude Capital Management's IMNM Position: Q2 2025 in Review

Prelude Capital Management sold out of Immunome (IMNM) in Q2 2025, closing a stake of 80,742 shares — an estimated $543K sold.

Prelude Capital Management first reported a position in IMNM in Q1 2025 and held it in 1 quarter. The position peaked at $543K in Q1 2025. 142 funds tracked by Wall St. Rank hold IMNM as of Q2 2025.

  • Prelude Capital Management reported no remaining Immunome position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 80,742 Immunome shares in Q2 2025, an estimated $543K.
  • Prelude Capital Management first reported a position in Immunome in Q1 2025 and held it in 1 quarter.
  • Prelude Capital Management's Immunome position peaked at $543K in Q1 2025.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.